Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia
Steven P. Treon(Dana-Farber Cancer Institute), Jorge J. Castillo(Dana-Farber Cancer Institute), Amanda Kofides(Shaanxi Research Association for Women and Family), Gloria Chan(Shaanxi Research Association for Women and Family), Maria Demos(Shaanxi Research Association for Women and Family), Noopur Raje(Massachusetts General Hospital), Nicholas Tsakmaklis(Shaanxi Research Association for Women and Family), Andrew J. Yee(Harvard University), Elizabeth O’Donnell(Harvard University), Xia Liu(Shaanxi Research Association for Women and Family), Manit Munshi(Dana-Farber Cancer Institute), Joshua Gustine(Boston University), Kirsten Meid(Shaanxi Research Association for Women and Family), Jiaji G. Chen(Shaanxi Research Association for Women and Family), Toni Dubeau(Shaanxi Research Association for Women and Family), Guang Yang(Blueprint Medicines (United States)), Lian Xu(Huazhong Agricultural University), Zachary R. Hunter(Harvard University)
Cited by 176
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
|Blood|2001|905
Immunopathology of Hyperinflammation in COVID-19
|American Journal Of Pathology|2020|526